More about Abbott India Limited
Fundamentals for Abbott India Limited
Regulatory Filings for Abbott India Limited
IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for Abbott India Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.
Revenue projections:
With Abbott India Limited's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.
Financial Ratios:
| currentRatio | 0.000000 |
|---|---|
| forwardPE | 32.471577 |
| debtToEquity | 4.549000 |
| earningsGrowth | 0.042000 |
| revenueGrowth | 0.068000 |
| grossMargins | 0.464090 |
| operatingMargins | 0.257940 |
| trailingEps | 716.310000 |
| forwardEps | 817.022200 |
ABBOTINDIA's positive gross and operating margins suggest strong profitability. These margins reflect effective cost management and revenue generation, indicating that the company is efficiently managing its operations and maintaining financial health.
ABBOTINDIA's forward EPS being higher than its trailing EPS suggests that the company is expected to generate stronger profits this year. This points to improving financial performance, with ABBOTINDIA anticipated to deliver better earnings than it did in the prior year.
Price projections:
The price of ABBOTINDIA has regularly been close to the lower end of projections, suggesting that it might be struggling to meet market expectations. This trend raises questions about the company's future performance.
Recommendation changes over time:
Analysts have shown a buy bias for ABBOTINDIA, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to ABBOTINDIA, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape